Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 12/20 | 0.52 |
| ▸ | CA1 | P00915 | 8/20 | 0.52 |
| ▸ | CA12 | O43570 | 2/20 | 0.52 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.52 |
| ▸ | CA7 | P43166 | 1/20 | 0.52 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | CA9 | Q16790 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL3349995 | 0.97 | CA2 (0.50) | CA2CA1CA12CA14CA7 | |
| SCHEMBL28163256 | 0.90 | CA2 (0.48) | CA2CA1CA12CA14CA7 | |
| SCHEMBL276730 | 0.89 | CA2 (0.44) | CA2CA1CA12CA14CA7 | |
| SCHEMBL18595186 | 0.81 | CA2 (0.47) | CA2CA1CA12CA14CA7 | |
| SCHEMBL224527 | 0.78 | CA1 (0.34) | CA2CA1CA12CA14CA7 | |
| SCHEMBL225628 | 0.77 | CA2 (0.40) | CA2CA1CA12CA14CA7 | |
| SCHEMBL7657072 | 0.77 | CA2 (0.40) | CA2CA1CA12CA14CA7 | |
| SCHEMBL21124793 | 0.77 | CA2 (0.40) | CA2CA1CA12CA14CA7 | |
| SCHEMBL3795708 | 0.77 | ALDH1A1 (0.52) | CA2CA1CA12CA14CA7 | |
| SCHEMBL2232711 | 0.76 | CA12 (0.43) | CA2CA1CA12CA14CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080161325-A1 | e.g. N1-[3-amino-4-(3,5-difluorophenyl)-2-hydroxybutyl]-3-(butylsulfonyl)-N1-(3-ethylbenzyl)-D-alaninamide dihydrochloride; inhibitors of amyloid beta-secretase enzyme; neurodegenerative diseases: Alzheimer's, Parkinson's diseases, Down's syndrome | ELAN PHARMACEUTICALS, INC. | 2008-07-03 | — | — | US | claimed |
| EP-1565428-A1 | SUBSTITUTED UREAS AND CARBAMATES | Elan Pharmaceuticals, Inc. (US) | 2005-08-24 | — | — | EP | claimed |
| EP-1534693-A2 | 1, 3-DIAMINO-2-HYDROXYPROPANE PRODRUG DERIVATIVES | Elan Pharmaceuticals, Inc. (US) | 2005-06-01 | — | — | EP | claimed |
| EP-1453789-A2 | N,N'-SUBSTITUTED-1,3-DIAMINO-2-HYDROXYPROPANE DERIVATIVES | Elan Pharmaceuticals, Inc. (US) | 2004-09-08 | — | — | EP | claimed |
| WO-2004050609-A1 | SUBSTITUTED UREAS AND CARBAMATES | ELAN PHARMACEUTICAL, INC. (US) | 2004-06-17 | — | — | WO | claimed |
| WO-2004022523-A2 | 1, 3-DIAMINO-2-HYDROXYPROPANE PRODRUG DERIVATIVES | ELAN PHARMACEUTICALS, INC. (US) | 2004-03-18 | — | — | WO | claimed |
| WO-2003040096-A2 | N, N'-SUBSTITUTED-1,3-DIAMINO-2-HYDROXYPROPANE DERIVATIVES | ELAN PHARMACEUTICALS, INC. (US) | 2003-05-15 | — | — | WO | claimed |
| EP-1565428-A1 | SUBSTITUTED UREAS AND CARBAMATES | Elan Pharmaceuticals, Inc. (US) | 2005-08-24 | — | — | EP | disclosed |
| WO-2004050609-A1 | SUBSTITUTED UREAS AND CARBAMATES | ELAN PHARMACEUTICAL, INC. (US) | 2004-06-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080161325-A1 | e.g. N1-[3-amino-4-(3,5-difluorophenyl)-2-hydroxybutyl]-3-(butylsulfonyl)-N1-(3-ethylbenzyl)-D-alaninamide dihydrochloride; inhibitors of amyloid beta-secretase enzyme; neurodegenerative diseases: Alzheimer's, Parkinson's diseases, Down's syndrome | BACE1, APP, BACE2 | CA2 2723/4885CA1 1011/4885CA12 4081/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.